Schering-Plough tries to deal its way to top
Article Abstract:
U.S. pharmaceutical company Schering-Plough Corp. is moving ahead with its $14.4 billion acquisition of Dutch firm Organon BioSciences N.V. Schering-Plough CEO Fred Hassan, who has spent the past four years improving the company's financial health, hopes that this acquisiton will lead to increased market share.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Novartis's net drops 45%, hit by generics
Article Abstract:
Fourth-quarter net profit for Novartis AG fell 45% to $904 mil, driven down by competition from generic drugs, a product withdrawal, and a restructuring charge. Total sales rose 6% to $9.93 bil; sales in the US dropped 15% to reach $3.07 bil.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Serono takes itself off the block. Novartis posts 4.1% rise in earnings. Serono's net profit rises 72% on lower costs
- Abstracts: H-P shifts focus to retail printing with photo kiosks. H-P net jumps amid a shift in strategic focus. Gateway to pay Hewlett-Packard $47 million in patent settlement
- Abstracts: Schering-Plough net leaps; Merck & Lilly notch gains. Schering-Plough posts leap in net: Merck profit sinks. Pace of Schering's rebound could ease
- Abstracts: UBS's income declines 47%. UBS posts 47% rise in net profit. Credit Suisse's net climbs 36% on investment-banking growth
- Abstracts: Commerzbank net soars, aided by trading income. Commerzbank's net rises 56% despite subprime write-downs. Commerzbank's net nearly doubles on sale in Korea Exchange Bank